doxorubicin + nebivolol

Doxorubicin is a cytotoxic anthracycline antibiotic used to treat various cancers, including breast, lung, gastric, ovarian, thyroid cancers, lymphomas (Hodgkin’s and non-Hodgkin’s), multiple myeloma, sarcomas, and pediatric cancers. Its mechanism of action involves DNA intercalation leading to DNA damage and generation of reactive oxygen species. Nebivolol is a selective beta-1 adrenergic receptor antagonist with vasodilatory properties via endothelial nitric oxide synthase stimulation; it is primarily used for hypertension but has shown cardioprotective effects against doxorubicin-induced cardiotoxicity in preclinical studies[1][4][5]. The combination of doxorubicin + nebivolol is not an approved or marketed product but has been studied for its potential to reduce chemotherapy-induced cardiotoxicity.

Other names

doxorubicin and nebivolol